Key Initiatives

The Challenge: Current standards of care fail to recognize the full scope of conditions affected by Alpha-1 Antitrypsin deficiency and the therapeutic potential of AAT supplementation.

Our Action Plan:

Publishing Mark's Discoveries

• Peer-reviewed journal publications of Mark's patent findings
• Case studies demonstrating successful AAT interventions
• White papers for medical professionals
• Clinical practice guidelines proposals

Physician Direct Engagement

• CME-accredited educational programs
• Grand rounds at major medical centers
• Specialty-specific training modules
• "Uniting Doctors" network expansion

Professional Society Collaboration

• Presenting at major medical conferences
• Working with guideline committees
• Partnering with specialty organizations
• Building consensus for change

Updated Clinical Guidelines

• American Thoracic Society guideline revision
• European Respiratory Society standards update
• Rheumatology, hepatology, neurology guideline integration
• Primary care screening protocols

Insurance Coverage Expansion

• Advocacy for broader testing coverage
• Treatment authorization criteria expansion
• Preventive therapy coverage
• Alternative formulation approvals

Medical Education Integration

• AATD modules in medical school curricula
• Residency program education requirements
• Board exam content inclusion
• Continuing education mandates

Comprehensive Standard of Care

• Routine screening in at-risk populations
• Early intervention before symptoms appear
• Treatment based on systemic manifestations, not just lung function
• Recognition of AAT therapy for 152 autoimmune diseases
• Prevention protocols for high-risk individuals

Measurable Success Indicators:

• ✓ Diagnosis time reduced from 8 years to

The Opportunity: Mark's discoveries demonstrate that demand for Alpha-1 Antitrypsin far exceeds what human plasma donation can supply. Alternative production is not just desirable—it's essential.

Historical Context: Previous attempts at plant and animal-based AAT production showed promise but were abandoned when the market seemed limited to traditional AATD patients. Mark's work reveals the true market potential.

Our Action Plan:

Demonstrating Market Potential

• Economic analysis showing true patient population (millions, not thousands)
• Market projections for expanded indications
• Cost-benefit analyses for alternative production
• Return-on-investment modeling

Technology Revival and Advancement

• Identifying previous successful research projects
• Updating methodologies with current technology
• Leveraging synthetic biology advances
• Applying CRISPR and modern bioengineering

Building Public-Private Partnerships

• Connecting biotech startups with funding
• Facilitating university-industry collaborations
• Supporting FDA regulatory pathway navigation
• Creating production development consortia

Plant-Based AAT

• Rice grain expression systems (proven feasibility, needs scale-up)
• Tobacco plant bioreactors (high yield potential)
• Moss cultivation (Physcomitrella patens) - controlled environment
• Algae production (sustainable, scalable)

Animal-Based AAT

• Transgenic goat milk production (kg quantities per animal)
• Chicken egg production (existing infrastructure)
• Regenerative tissue culture (no whole animals needed)

Cellular Production

• CHO cell optimization (pharmaceutical industry standard)
• Yeast fermentation (cost-effective, scalable)
• Bacterial expression (fastest production)
• Insect cell systems (complex protein folding)

Gene Therapy as Production

• One-time treatment enabling patient's own AAT production
• AAV vectors with long-term expression
• CRISPR correction of genetic defects
• Ultimate goal: cure, not chronic therapy

Research Grants

• Seed funding for proof-of-concept studies
• Scale-up and manufacturing process development
• Safety and efficacy studies
• Regulatory approval support

Industry Incentives

• Connecting investors with opportunities
• Tax incentive advocacy
• Orphan drug designation benefits
• Market exclusivity considerations

Expected Timeline:

• 2025-2026: Proof-of-concept studies funded
• 2027-2028: Lead platforms identified, scale-up initiated
• 2029-2030: FDA submissions, first approvals
• 2031+: Multiple production sources available, costs reduced 50-90%

The Reality: Most physicians receive minimal or no education about AATD, and virtually none learn about AAT's broader therapeutic applications.

Our Vision: Every medical professional should understand AATD, recognize when to test, and know how AAT therapy can benefit their patients.

Multi-Level Education Strategy:

Pre-Clinical Years

• Biochemistry: AAT as protease inhibitor model
• Pathology: Tissue damage from excess neutrophil elastase
• Genetics: Inheritance patterns and population genetics
• Immunology: AAT's role in inflammation control

Clinical Years

• Internal Medicine: AATD diagnosis and management
• Pulmonology rotation: Emphysema phenotypes
• Hepatology: Liver disease manifestations
• Rheumatology: Autoimmune disease connections

Deliverables:

• Curriculum modules for 100+ medical schools
• Interactive case studies and clinical vignettes
• Online learning platforms
• Assessment tools and competencies

Specialty-Specific Content

• Pulmonology: Advanced AATD management
• Hepatology: Liver disease prevention and treatment
• Rheumatology: AAT in autoimmune disease
• Neurology: Neuroinflammation and AAT
• Oncology: Cancer prevention and AAT
• Primary Care: Screening and early recognition

Teaching Methods:

• Didactic lectures and conferences
• Hands-on patient care experience
• Journal clubs reviewing latest research
• Multidisciplinary case conferences

Live Events

• Annual MEF medical conference
• Regional symposia and workshops
• Grand rounds at medical centers
• Specialty society conference presentations

Online Learning

• On-demand webinars
• Interactive case-based modules
• Podcast series for busy physicians
• Mobile app-based learning

Practice Tools

• Diagnostic algorithms and flowcharts
• Treatment protocols and guidelines
• Patient education materials
• Electronic health record (EHR) integration tools

Hospital Systems

• Department of Medicine presentations
• Quality improvement initiatives
• Standard order sets for AATD testing
• Treatment protocol implementation

Community Health Centers

• Screening programs for underserved populations
• Telemedicine consultation support
• Resource-appropriate protocols
• Population health approaches

Academic Medical Centers

• Research collaboration opportunities
• Clinical trial site development
• Faculty development programs
• Student and resident teaching

Metrics:

• Number of physicians completing training
• Knowledge assessment pre/post scores
• Testing rates before and after education
• Diagnosis rates in educated vs. non-educated practices
• Time to diagnosis improvements
• Treatment initiation rates

Goal: Every physician trained by 2030, with measurable improvements in patient outcomes.

The Need: Public awareness is critically low. Most people have never heard of AATD, and even those affected often go undiagnosed for years.

Target Audiences:

Mass Media Campaigns

• Public service announcements (TV, radio, digital)
• Social media awareness campaigns
• Celebrity and influencer partnerships
• Documentary production and distribution

Digital Presence

• Comprehensive educational website
• YouTube channel with patient stories and expert interviews
• Podcasts reaching diverse audiences
• Mobile apps for symptom checking and resources

Community Outreach

• Health fairs and screening events
• Workplace wellness programs
• Faith-based organization partnerships
• Community center presentations

High-Priority Groups

• Non-smokers with COPD or emphysema
• Individuals with unexplained liver disease
• Families with clustering of early deaths
• Patients with multiple autoimmune conditions
• Chronic pain sufferers with no clear diagnosis

Targeted Messaging

• "Non-smoker with COPD? Get tested for Alpha-1"
• "Early emphysema runs in families - find out why"
• "One simple blood test could explain everything"
• "Your chronic pain might have a treatable cause"

Newly Diagnosed

• "What Now?" comprehensive guide
• Peer support group connections
• Treatment options overview
• Genetic counseling resources

Living with AATD

• Lifestyle management strategies
• Environmental protection tips
• Insurance navigation support
• Clinical trial opportunities

Family Members

• Understanding inheritance patterns
• When and how to get tested
• Supporting affected loved ones
• Risk reduction strategies

Alpha-1 Awareness Month (November)

• National media push
• Social media campaigns (#Alpha1Awareness)
• Awareness walks and fundraising events
• Recognition proclamations from officials

Year-Round Initiatives

• Patient story sharing
• Research milestone announcements
• Policy victory celebrations
• Community success stories

Expected Impact:

• 10 million+ people reached annually
• 1,000,000+ individuals requesting testing
• 100,000+ new diagnoses per year (vs. currently less than 2,000)
• Diagnosis time cut in time by 95%

Philosophy: We can't wait for perfect solutions. Existing knowledge and treatments can save lives right now.

Immediate Life-Saving Actions:

Targeted Screening

• Free testing for high-risk individuals
• Mobile screening units
• Mail-in testing kits
• Partnership with existing health screenings
• Newborm Blood Panel

Rapid Diagnosis Pathways

• Same-day genotyping when possible
• Expedited confirmatory testing
• Immediate specialist referral
• Fast-track to treatment

Insurance Authorization Assistance

• Expert letters of medical necessity
• Appeal support for denials
• Documentation and evidence compilation
• Legal advocacy when needed

Financial Assistance Programs

• Patient assistance program connections
• Co-pay support
• Travel grants for treatment access
• Medication access programs

Carrier State Management

• Environmental protection education
• Occupational exposure counseling - such as Military and First Responders
• Lifestyle modification support
• Monitoring for early disease signs

At-Risk Family Members

• Cascade testing programs
• Genetic counseling
• Preventive strategy development
• Regular monitoring protocols

Trial Matching Services

• Patient-trial matching algorithms
• Clinical trial navigation support
• Travel and lodging assistance
• Informed consent education

Research Participation

• Alpha-1 Research Registry enrollment
• Natural history study participation
• Biobank contributions
• Patient-reported outcome studies

Lives Saved:

Through earlier diagnosis, improved treatment access, and prevention strategies, we aim to prevent 1,000+ premature deaths annually by 2030.

Mark's Vision: These discoveries belong to the world. The medical community should take these findings and soar to heights we can't yet imagine.

How We're Empowering Innovation:

Knowledge Sharing

• Publishing all findings in peer-reviewed journals
• Making research data accessible
• Open-access publication when possible
• No proprietary restrictions on clinical use

Patent Strategy

• Protective patents prevent monopolization
• Licensing structured to maximize patient benefit
• No barriers to research use
• Affordable treatment prioritized over profit

"Uniting Doctors" Platform

• Online community for clinicians and researchers
• Case study sharing and discussion
• Collaborative research projects
• Mentorship and consultation

Research Resource Sharing

• Patient registries and databases
• Biobank access
• Research protocols and tools
• Data analysis support

Research Competitions

• Annual awards for breakthrough research
• Funding for novel approaches
• Recognition for clinical innovation
• Seed grants for unconventional ideas

Young Investigator Programs

• Training grants for early-career researchers
• Mentorship from leading experts
• Conference travel support
• Career development opportunities

New Treatment Protocols

• Support for physicians trying novel approaches
• Documentation and outcome tracking
• Publication assistance
• Protocol dissemination

Quality Improvement Projects

• Implementing systematic screening
• Treatment protocol optimization
• Outcome measurement and improvement
• Best practice sharing

Expected Outcomes:

• 100+ researchers actively investigating AAT applications
• 50+ novel research projects launched
• 20+ clinical innovations implemented
• Exponential growth in knowledge and applications

• Q1: Launch physician education program; Newborn blood panel implementation
• Q2: Begin public awareness campaigns
• Q3: Initiate alternative production partnerships
• Q4: Establish research collaboration networks

• Q1: 5,000 physicians trained
• Q2: First alternative production milestones
• Q3: Major medical conference presentations
• Q4: Policy advocacy initiatives launched

• Q1: First guideline updates published
• Q2: Half of all physicians trained
• Q3: Clinical trial results emerging
• Q4: Insurance coverage expansions

• Q1: Alternative AAT production scaling
• Q2: All physicians trained
• Q3: Widespread protocol adoption
• Q4: International expansion

• Standard of care fully transformed
• Multiple AAT sources available
• Prevention programs established
• Global reach achieved

Diagnosis Metrics

• Average time to diagnosis
• Number of new diagnoses annually
• Testing rates in at-risk populations
• Percentage diagnosed at early stages

Treatment Metrics

• Treatment initiation rates
• Average time from diagnosis to treatment
• Treatment adherence rates
• Patient-reported outcomes

Education Metrics

• Physicians trained
• Medical students reached
• Public awareness levels
• Website traffic and engagement

Research Metrics

• Publications produced
• Clinical trials initiated
• Research funding secured
• New investigators engaged

Impact Metrics

• Lives saved
• Quality-adjusted life years gained
• Healthcare costs reduced
• Patient satisfaction scores

Patients and Families

• Share your story
• Participate in research
• Advocate for change
• Educate others

Healthcare Providers

• Get trained on AATD
• Test more liberally
• Join our network
• Share your clinical experience

Researchers

• Apply for funding
• Collaborate with our network
• Publish your findings
• Mentor the next generation

Industry Partners

• Develop alternative production
• Support research
• Improve diagnostics
• Expand treatment access

Donors and Supporters

• Fund specific initiatives
• Sponsor education programs
• Support research projects
• Amplify our message

Through these six key initiatives, the Mark Egly Foundation will:

• Transform standards of care across multiple medical specialties
• Revitalize alternative AAT production, making therapy affordable and accessible globally
• Educate every medical professional about AATD and AAT's therapeutic potential
• Empower the public to recognize symptoms and seek testing
• Save thousands of lives through early diagnosis and prevention
• Enable the medical community to discover applications beyond our current imagination

Mark Egly spent 45 years searching for answers to his family's tragic health history. His discoveries revealed truths that will save millions of lives. But this was never about Mark alone—it was always about the countless families suffering from undiagnosed disease.

Now it's time for the world to take these discoveries and run with them.

The Mark Egly Foundation provides the launchpad—the education, the research support, the advocacy platform, the collaborative networks. We're removing every barrier we can so that medical professionals worldwide can innovate, discover, and heal.

How high can medicine soar with these discoveries?

Let's find out together.

For information about supporting specific initiatives, collaboration opportunities, or getting involved, contact the Mark Egly Foundation.

Every initiative. Every action. Every life saved. This is Mark's legacy becoming reality.